IGM Biosciences Inc (IGMS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, IGM Biosciences Inc (IGMS) has a cash flow conversion efficiency ratio of -0.503x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-50.79 Million) by net assets ($100.93 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See IGM Biosciences Inc defensive interval ratio to measure how many days the company can operate on defensive assets alone.
IGM Biosciences Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how IGM Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
IGM Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of IGM Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NexLiving Communities Inc
V:NXLV
|
0.019x |
|
Athanase Innovation AB
ST:ATIN
|
-0.026x |
|
FlexQube AB
ST:FLEXQ
|
0.195x |
|
ZENTEK LTD.
F:ZAY0
|
-0.158x |
|
ROK Resources Inc
V:ROK
|
0.003x |
|
Southern Rubber Industry JSC
VN:CSM
|
0.143x |
|
Arrow Syndicate Public Company Limited
BK:ARROW
|
0.052x |
|
Heungkuk Metaltech Co.Ltd
KQ:010240
|
0.061x |
Annual Cash Flow Conversion Efficiency for IGM Biosciences Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of IGM Biosciences Inc from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see IGMS stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $48.17 Million | $-153.00 Million | -3.176x | -235.78% |
| 2023-12-31 | $203.23 Million | $-192.23 Million | -0.946x | -4542.25% |
| 2022-12-31 | $287.26 Million | $-5.85 Million | -0.020x | +95.99% |
| 2021-12-31 | $244.91 Million | $-124.34 Million | -0.508x | -188.02% |
| 2020-12-31 | $381.81 Million | $-67.30 Million | -0.176x | +6.14% |
| 2019-12-31 | $240.23 Million | $-45.12 Million | -0.188x | -161.68% |
| 2018-12-31 | $-65.83 Million | $-20.04 Million | 0.304x | +19.08% |
| 2017-12-31 | $-40.50 Million | $-10.36 Million | 0.256x | -- |
About IGM Biosciences Inc
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M antibodies for the treatment of cancer and autoimmune and inflammatory diseases. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California. As of August 14, 2025, IGM Biosciences, In… Read more